Glioblastoma vs temozolomide: can the red queen race be won?

References

• Thakkar, J. P. 2014. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 23:1985–1996. doi:10.1158/1055-9965.EPI-14-0275.
   PubMed Web of Science ®Google Scholar
• O‘Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur J Cancer. 1993;29A:940–942.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, van Den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. 2009. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. doi:10.1016/S1470-2045(09)70025-7.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van Den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. doi:10.1056/NEJMoa043330.
   PubMed Web of Science ®Google Scholar
• Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development, and clinical trials. Cancer Treat Rev. 1997;23:35–61.
   PubMed Web of Science ®Google Scholar
• Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987;47:5846–5852.
   PubMed Web of Science ®Google Scholar
• Brada M, Stenning S, Gabe R, Thompson LC, Levy D, Rampling R, Erridge S, Saran F, Gattamaneni R, Hopkins K, et al. 2010. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol. 28:4601–4608. doi:10.1200/JCO.2009.27.1932.
   PubMed Web of Science ®Google Scholar
• Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, et al. 2000. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 83:588–593. doi:10.1054/bjoc.2000.1316.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. 2005. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352:997–1003. doi:10.1056/NEJMoa043331.
   PubMed Web of Science ®Google Scholar
• Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al. 2013. The somatic genomic landscape of glioblastoma. Cell. 155:462–477. doi:10.1016/j.cell.2013.09.034.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research, N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–1068. doi:10.1038/nature07385.
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17:98–110. doi:10.1016/j.ccr.2009.12.020.
   PubMed Web of Science ®Google Scholar
• Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, et al. 2017. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomized, double-blind, international phase 3 trial. Lancet Oncol. 18:1373–1385. doi:10.1016/S1470-2045(17)30517-X.
   PubMed Web of Science ®Google Scholar
• Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, et al. 2014. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 343:72–76. doi:10.1126/science.1241328.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. 2016. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131:803–820. doi:10.1007/s00401-016-1545-1.
   PubMed Web of Science ®Google Scholar
• Leu S, von Felten S, Frank S, Vassella E, Vajtai I, Taylor E, Schulz M, Hutter G, Hench J, Schucht P, et al. 2013. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro-oncol. 15:469–479. doi:10.1093/neuonc/nos317.
   PubMed Web of Science ®Google Scholar
• Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, et al. 2014. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 370:709–722. doi:10.1056/NEJMoa1308345.
   PubMed Web of Science ®Google Scholar
• Lipinski C, Hopkins A. 2004. Navigating chemical space for biology and medicine. Nature. 432:855–861. doi:10.1038/nature03193.
   PubMed Web of Science ®Google Scholar
• Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol. 2006. 689–700. doi:10.1038/nchembio840.
   PubMed Web of Science ®Google Scholar
• Stevens MF, Newlands ES. From triazines and triazenes to temozolomide. Eur J Cancer. 1993;29A:1045–1047.
   PubMed Web of Science ®Google Scholar
• Goodman LS, Wintrobe MM. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin‘s disease, lymphosarcoma, leukemia, and certain allied and miscellaneous disorders. J Am Med Assoc. 1946;132:126–132.
   PubMed Web of Science ®Google Scholar
• Wintrobe MM. Nitrogen mustard therapy. Am J Med. 1948;4:313.
   PubMed Web of Science ®Google Scholar
• Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature. 1953;171:737–738.
   PubMed Web of Science ®Google Scholar
• Zhang J, Stevens MF, Bradshaw TD. Temozolomide: mechanisms of action, repair, and resistance. Curr Mol Pharmacol. 2012;5:102–114.
   PubMedGoogle Scholar
• Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W. 2008. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 14:2900–2908. doi:10.1158/1078-0432.CCR-07-1719.
   PubMed Web of Science ®Google Scholar
• Wick W, Platten M. 2014. Understanding and targeting alkylator resistance in glioblastoma. Cancer Discov. 4:1120–1122. doi:10.1158/2159-8290.CD-14-0918.
   PubMed Web of Science ®Google Scholar
• Kaina B, Christmann M, Naumann S, Roos WP. 2007. MGMT: a key node in the battle against genotoxicity, carcinogenicity, and apoptosis induced by alkylating agents. DNA Repair (Amst). 6:1079–1099. doi:10.1016/j.dnarep.2007.03.008.
   PubMed Web of Science ®Google Scholar
• Wick W, Weller M, van Den Bent M, Sanson M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M, Reifenberger G. 2014. MGMT testing–the challenges for biomarker-based glioma treatment. Nat Rev Neurol. 10:372–385. doi:10.1038/nrneurol.2014.100.
   PubMed Web of Science ®Google Scholar
• van Nifterik KA, van Den Berg J, van der Meide WF, Ameziane N, Wedekind LE, Steenbergen RDM, Leenstra S, Lafleur MVM, Slotman BJ, Stalpers LJA, et al. 2010. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. Br J Cancer. 103:29–35. doi:10.1038/sj.bjc.6605712.
   PubMed Web of Science ®Google Scholar
• Tang K, Jin Q, Yan W, Zhang W, You G, Liu Y, Jiang T. 2012. Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients. Med oncol. 29:1292–1296. doi:10.1007/s12032-011-9901-4.
   PubMed Web of Science ®Google Scholar
• Wickstrom, M. 2015. Wnt/beta-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signaling prevents chemoresistance. Nat Commun. 6:8904. doi:10.1038/ncomms9904.
   PubMed Web of Science ®Google Scholar
• Liu L, Gerson SL. 2006. Targeted modulation of MGMT: clinical implications. Clin Cancer Res. 12:328–331. doi:10.1158/1078-0432.CCR-05-2543.
   PubMed Web of Science ®Google Scholar
• Kim H, Zheng S, Amini SS, Virk SM, Mikkelsen T, Brat DJ, Grimsby J, Sougnez C, Muller F, Hu J, et al. 2015. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveal patterns of tumor evolution. Genome Res. 25:316–327. doi:10.1101/gr.180612.114.
   PubMed Web of Science ®Google Scholar
• McFaline-Figueroa JL, Braun CJ, Stanciu M, Nagel ZD, Mazzucato P, Sangaraju D, Cerniauskas E, Barford K, Vargas A, Chen Y, et al. 2015. Minor changes in expression of the mismatch repair protein MSH2 exert a major impact on glioblastoma response to temozolomide. Cancer Res. 75:3127–3138. doi:10.1158/0008-5472.CAN-14-3616.
   PubMed Web of Science ®Google Scholar
• Krokan HE, Bjoras M. 2013. Base excision repair. Cold Spring Harb Perspect Biol. 5:a012583. doi:10.1101/cshperspect.a012583.
   PubMed Web of Science ®Google Scholar
• Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. 2005. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res. 65:6394–6400. doi:10.1158/0008-5472.CAN-05-0715.
   PubMed Web of Science ®Google Scholar
• Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, et al. 2012. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest. 122:253–266. doi:10.1172/JCI59334.
   PubMed Web of Science ®Google Scholar
• Murphy SF, Varghese RT, Lamouille S, Guo S, Pridham KJ, Kanabur P, Osimani AM, Sharma S, Jourdan J, Rodgers CM, et al. 2016. Connexin 43 inhibition sensitizes chemoresistant glioblastoma cells to temozolomide. Cancer Res. 76:139–149. doi:10.1158/0008-5472.CAN-15-1286.
   PubMed Web of Science ®Google Scholar
• Munoz, J. L. 2014. Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43. Cell Death Dis. 5:e1145. doi:10.1038/cddis.2014.111.
   PubMed Web of Science ®Google Scholar
• Munoz JL, Walker ND, Scotto KW, Rameshwar P. 2015. Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells. Cancer Lett. 367:69–75. doi:10.1016/j.canlet.2015.07.013.
   PubMed Web of Science ®Google Scholar
• Weatherbee JL, Kraus JL, Ross AH. 2016. ER stress in temozolomide-treated glioblastomas interferes with DNA repair and induces apoptosis. Oncotarget. 7:43820–43834. doi:10.18632/oncotarget.9907.
   PubMedGoogle Scholar
• Zhang WB, Wang Z, Shu F, Jin Y-H, Liu H-Y, Wang Q-J, Yang Y. 2010. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem. 285:40461–40471. doi:10.1074/jbc.M110.164046.
   PubMed Web of Science ®Google Scholar
• Yi GZ, Liu Y-W, Xiang W, Wang H, Chen Z-Y, Xie S-D, Qi S-T. 2016. Akt and beta-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line. J Neurol Sci. 367:101–106. doi:10.1016/j.jns.2016.05.054.
   PubMed Web of Science ®Google Scholar
• Wick W, Platten M, New WM. 2009. (Alternative) temozolomide regimens for the treatment of glioma. Neuro-oncol. 11:69–79. doi:10.1215/15228517-2008-078.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, et al. 2013. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 31:4085–4091. doi:10.1200/JCO.2013.49.6968.
   PubMed Web of Science ®Google Scholar
• Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, et al. 2008. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol. 26:5603–5609. doi:10.1200/JCO.2008.18.0612.
   PubMed Web of Science ®Google Scholar
• Wick W, Gorlia T, Bady P, Platten M, van Den Bent MJ, Taphoorn MJB, Steuve J, Brandes AA, Hamou M-F, Wick A, et al. 2016. Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Clin Cancer Res. 22:4797–4806. doi:10.1158/1078-0432.CCR-15-3153.
   PubMed Web of Science ®Google Scholar
• Mason WP, Cairncross JG. 2005. Drug insight: temozolomide as a treatment for malignant glioma–impact of a recent trial. Nat Clin Pract Neurol. 1:88–95. doi:10.1038/ncpneuro0045.
   PubMedGoogle Scholar
• Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, et al. 2014. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 370:699–708. doi:10.1056/NEJMoa1308573.
   PubMed Web of Science ®Google Scholar
• Bienkowski M, Berghoff AS, Marosi C, Wöhrer A, Heinzl H, Hainfellner JA, Preusser M. Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions. Clin Neuropathol. 2015;34:250–257.
   PubMed Web of Science ®Google Scholar